复星医药(02196)：膦甲酸钠注射液药品注册申请获国家药监局受理

智通财经04-17

智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。该新药系化学药品，拟用于获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。截至2024年3月，该集团现阶段针对该新药的累计研发投入约为人民币...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2428397685?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-17 17:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2428397685","market":"us","top_or_hot":-1,"title":"复星医药(02196)：膦甲酸钠注射液药品注册申请获国家药监局受理","media":"智通财经","content":"<div>\n<p>智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。该新药系化学药品，拟用于获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。截至2024年3月，该集团现阶段针对该新药的累计研发投入约为人民币...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1103928.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复星医药(02196)：膦甲酸钠注射液药品注册申请获国家药监局受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复星医药(02196)：膦甲酸钠注射液药品注册申请获国家药监局受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-17 17:47 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1103928.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。该新药系化学药品，拟用于获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。截至2024年3月，该集团现阶段针对该新药的累计研发投入约为人民币...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1103928.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1103928.html","article_id":"2428397685","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2428397685","pubTimestamp":1713347265,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，复星医药 发布公告，该公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液的药品注册申请于近日获国家药品监督管理局受理。截至2024年3月，该集团现阶段针对该新药的累计研发投入约为人民币417万元。根据IQVIA CHPA最新数据，2022年，膦甲酸钠注射剂于中国境内的销售额约为人民币7672万元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1191":"制药","BK1593":"医美概念股","BK1515":"抗疫概念","02196":"复星医药"},"translate_title":"Fosun Pharma (02196): The drug registration application for foscarnet injection has been accepted by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02196":1},"content_text":"智通财经APP讯，复星医药(02196)发布公告，该公司控股子公司桂林南药股份有限公司的膦甲酸钠注射液(以下简称“该新药”)的药品注册申请于近日获国家药品监督管理局受理。该新药系化学药品，拟用于获得性免疫缺陷综合征(AIDS)患者的巨细胞病毒性(CMV)视网膜炎;免疫功能低下患者的耐阿昔洛韦单纯疱疹病毒性(HSV)的皮肤黏膜感染。截至2024年3月，该集团现阶段针对该新药的累计研发投入约为人民币417万元(未经审计)。截至本公告日，于中国境内(不包括港澳台地区，下同)已获批上市的膦甲酸钠注射剂主要包括正大天晴药业集团股份有限公司的可耐(膦甲酸钠氯化钠注射液)、远大医学营养科学(武汉)有限公司的安济®(膦甲酸钠氯化钠注射液)、广东宏远集团药业有限公司的宏远易抗®(注射用膦甲酸钠)等。根据IQVIA CHPA最新数据，2022年，膦甲酸钠注射剂于中国境内的销售额约为人民币7672万元。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2428397685"}